Plant-derived terpenes in treating patients with urolithiasis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Numerous metabolic abnormalities intrinsic to urolithiasis require drug therapy. At the same time, despite the constant expansion of synthetic drugs, plant-derived medications play a large role in the treatment and prevention of the disease. Aim. To evaluate the effect of a plant-derived preparation Rowatinex in patients with urolithiasis after extracorporeal shock wave lithotripsy (ESWL) and analyze the changes in blood and urine parameters in patients receiving the preparation. Materials and methods. Depending on the type of post-ESWL treatment, patients were divided into two groups. After ESWL, patients of group A (n=107) and group B (n=50) were administered Rowatinex and antispasmodic drugs, respectively. Results and discussion. Clearance of stone fragments after ESWL within 1-5 days was achieved in 76 (71.1%) patients of group A and in 20 (40.4%) of group B. Analysis of the effect of the therapy on blood count, biochemistry tests and 24h excretion (magnesium, uric acid, calcium, etc.) did not reveal significant differences between group A group B and reference values. Increased diuresis caused by antispasmodic effects of Rowatinex resulted in the complete clearance of stone fragments. Urinalysis in patients of the two groups showed decreased leukocyturia. Furthermore, stabilization of urine pH within the 6.2-6.8 was noted in group A, which is important and necessary in metaphylaxis of recurrent stone formation. Conclusions. Administration of Rowatinex increases the percentage of stone fragment clearance after ESWL and reduces pain intensity. Rowatinex reduces leukocyturia, increases 24h diuresis and stabilizes the pH of urine. Increasing and stabilizing urine pH in patients with calcium oxalate and urate stones reduces the risk of recurrence after ESWL. No complications associated with Rowatinex were reported, allowing longterm administration of the preparation in the complex lithokinetic therapy and for metaphylaxis of recurrent stone formation.

Full Text

Restricted Access

About the authors

Yu. G Alyaev

Sechenov First Moscow State Medical University

Department of Urology

V. I Rudenko

Sechenov First Moscow State Medical University

Email: rudenko-vadim@rambler.ru
Department of Urology

A. N Perekalina

Sechenov First Moscow State Medical University

Department of Urology

I. G Kraev

Sechenov First Moscow State Medical University

Email: i_kraev@list.ru
Department of Urology

Zh. Sh Inoyatov

Sechenov First Moscow State Medical University

Email: inoyat@yandex.ru
Department of Urology

References

  1. Fisang C., Anding R., Müller S.C., Latz S., Laube N. Urolithiasis an interdisciplinary diagnostic, therapeutic and secondary preventive challenge. Deutsches Arzteblatt International. 2015; 112(6): 83-91.
  2. Аляев Ю.Г., Амосов А.В., Саенко В.С. Метафилактика мочекаменной болезни. М.: ЭКСМО, 2007
  3. Черепанова Е.В., Дзеранов Н.К. Метафилактика мочекаменной болезни в амбулаторных условиях. Экспериментальная и клиническая урология. 2013; 3: 33-39
  4. Дзеранов Н.К., Борисов В.В. Консервативная литокинетическая терапия камней почек и мочеточников. М.: Оверлей, 2009. 72 c.
  5. Аполихин О.И., Сивков А.В., Бешлиев Д.А., Солнцева Т.В., Комарова В.А. Анализ уронефрологической заболеваемости в Российской Федерации по данным официальной статистики. Экспериментальная и клиническая урология. 2010; 1: 4-11
  6. Голованов С.А., Дзеранов Н.К. Кристаллообразующая активность мочи при оксалатном уролитиазе. Экспериментальная и клиническая урология. 2010; 2: 24-29
  7. Дзеранов Н.К., Лопаткин Н.А. Мочекаменная болезнь: клинические рекомендации. М.: «Оверлей», 2007. 296 c.
  8. Сивков А.В., Черепанова Е.В., Шадеркина В.А. Применение фитопрепаратов на основе терпенов при мочекаменной болезни. Экспериментальная и клиническая урология. 2011; 1: 69-72
  9. Сивков А.В., Дзеранов Н.К., Черепанова Е.В., Константинова О.В., Голованов С.А., Шадеркина В.А. Результаты применения препарата Роватинекс у больных, страдающих уролитиазом. Экспериментальная и клиническая урология. 2011; 4: 38-45
  10. Ермоленко Т.И. Перспективы применения фитопрепаратов в лечении мочекаменной болезни. Фармация и фармакология. 2014; 18: 205-211
  11. Максимов В.А., Яровой С.К., Александров Н.С., Максудов Р.Р. Место фитотерапии в лечении мочекаменной болезни. Урология. 2012; 3
  12. Sybilska D., Asztemborska M. Chiral recognition of terpenoids in some pharmaceuticals derived from natural sources. J. Biochem Biophys Methods. 2002; 54(1-3): 187-195.
  13. Chua M.E., Park J.H., Castillo J.C. Terpene compound drug as medical expulsive therapy for ureterolithiasis: a meta - analysis. Urolithiasis. 2013; 41(2): 143-151.
  14. Lee J.W., Lee M.Y., Park S.C. et al. In vitro Study on Ureteral Smooth Muscle Relaxation with Tamsulosin, Nifedipine, and Terpene mixure (Rowatinex). Eur. Urol. 2013; 12(1)Suppl.17.
  15. Romics I., Siller G., Kohnen R., Mavrogenis S., Varga J., Holman E. A special terpenes combination (Rowatinex®) improves stone clearance after extracorporeal shockwave lithotripsy in urolithiasis patients: results of a placebo-controlled randomized controlled trial. Urol Int. 2011; 86(1): 102-109.
  16. Djaladat H., Mahouri K., Khalifeh Shooshtary F., Ahmadieh A. Effect of Rowatinex on calculus clearance after extracorporeal shock wave lithotripsy. Urol. J. 2009; 6(1): 9-13.
  17. Попков В.М., Блюмберг Б.И., Основин О.В., Шатылко Т.В. Применение Роватинекса в периоперационном периоде при дистанционной ударно-волновой литотрипсии. Урология. 2012; 2: 25-27
  18. Азизов А.П. Применение Роватинекс® в лечении хронического пиелонефрита, осложненного нефролитиазом. Фарматека. 2011; 20: 88-90
  19. Romics I., Kohnen R., Mavrogenis St., Varga J., Holman E., A Special Terpene Combination (Rowatinex) Improves Stone Clearance after Extracorporeal Shockwave Lithotripsy in Urolithiasis Patients: Results of a Placebo-Controlled Randomised Controlled Trial. Urologia Internationalis. 2011; 86: 102-109.
  20. Evan A.P., Worcester E.M., Coe F.L., Williams J. Jr, Lingeman J.E. Mechanisms of human kidney stone formation. Urolithiasis. 2015; 43(Suppl. 1): 19-32.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies